Health Care Experts Define Value in Oncology Business Practices

Share Article

Roundtable opens dialog on workable solutions.

We covered several key topics, and did this with the entire supply chain at the table together.

The massive business of cancer care features multiple voices, usually speaking from opposing platforms. While each constituent offers valuable insight into resolving issues holding back value-based care, few venues provide an effective format that brings these different perspectives together in a constructive way.

Recently, Lyceum Associates, Inc. aimed to fill this gap, through its unique brand of collaborative, analytical debate. The discussion explored oncology's manifold issues, and established a basis for assessing potential resolutions and market transitions.

The roundtable met at the University Club in New York City on January 15, 2008 and included senior executives from the following businesses and organizations: Amgen, Inc., Ancillary Care Management, Inc., the Biotechnology Industry Organization, CVS Caremark Corporation, DGH Consulting, Fighting Chance, Genomic Health, Inc., Horizon Blue Cross Blue Shield of New Jersey,, and NPS Pharmaceuticals, Inc.

"Lyceum hosted a fantastic forum," noted Richard Popiel, MD. "We covered several key topics, and did this with the entire supply chain at the table together." Dr. Popiel is the chief medical officer of Horizon Blue Cross Blue Shield.

Participants addressed the fundamentals of quality-of-care, evidence-based medicine, pay-for-performance and personalized medicine, and worked towards new strategies in plan design.

"Oncology therapies pose particular challenges for health plans and employers looking to better manage costs and improve outcomes," added Scott Reid, senior vice president at Caremark Pharmacy Services, a division of CVS Caremark. "By coming together to discuss these issues, we can open the door to collaboration and solutions."

Many highlighted the complexity of working with patient information, and the lack of standards which prevents seamless integration.

"As a biotechnology company developing new therapeutics, we enjoy the Lyceum community's unique perspectives on how to create value at each stage of the health care system," explained Robert Ward, head of business development for NPS Pharmaceuticals. "This is a great way for us to extend our network of contacts across the industry."

About Lyceum Associates
Lyceum Associates ( develops and manages information networks that connect a broad range of economic stakeholders on topics of industry and corporate transition. Members gain from uncommon access to strategic discussion and the networking opportunities that arise from this.

The Lyceum community features leading financial, corporate and industry professionals, all of whom interact as equal participants in offline and online settings. Many of the participants are current and former company founders and chief executives. Several of these individuals have contributed articles to the newsletter. This collaborative effort produces a truly customized experience.

Lyceum Associates, Inc. is a registered investment adviser.

Sydney Williams
Lyceum Associates, Inc.
(203) 542-5208
info @

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sydney Williams
Visit website